drugset / Trial / NCT05335473
Iribrine Plus Tucidinostat in the Treatment of HR+/HER2 Advanced Breast Cancer After CDK4/6 Inhibitor Failure
NaSingle-groupOpen-labelTreatment
Summary
To explore the safety and efficacy of Eribulin plus Tucidinostat amine in patients with HR+/ HER2-advanced metastatic breast cancer
Timeline
- Start
- 2022-05-13
- Primary completion
- 2025-05-01
- Completion
- 2025-11-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Eribulin | Small molecule | — | — |
| Subject | Tucidinostat | Small molecule | — | — |